Members
First name: Julie Last name: Bertrand Function: Researcher Email: julie.bertrand inserm.fr |
Research interest
I am a Biostatistician with an expertise in modelling pharmacokinetic/pharmacodynamic data.
My research focuses on the evaluation and development of new inference methods for dynamical processes in order to i) quantify treatment effect or bioequivalence, ii) identify genetic markers of the drug response, iii) jointly infer the survival of events of interest,...
In collaboration with clinicians, I have applied my methodological works to the analysis and design of several pharmacological studies.
Education
Degree
2009: Ph. D in Biomathematics, University Paris 7
Academic positions
2016-present: Research Fellow, UMR 1137 INSERM University Paris 7
2012-2015: Medical Research Council Research Fellow, University College London Genetics Institute
2010-2012: Research Associate , University College London Genetics Institute
2012-2015: Medical Research Council Research Fellow, University College London Genetics Institute
2010-2012: Research Associate , University College London Genetics Institute
Exhaustive list of publications
2024
Baudemont G, Tardivon C, Monneret G, Cour M, Rimmelé T, Garnier L, Yonis H, Richard JC, Coudereau R, Gossez M, Wallet F, Delignette MC, Dailler F, Buisson M, Lukaszewicz AC, Argaud L, Laouenan C, Bertrand J, Venet F, RICO study group
Joint modeling of monocyte HLA-DR expression trajectories predicts 28-day mortality in severe SARS-CoV-2 patients.
CPT: pharmacometrics & systems pharmacology 2024, 13, 1130-1143.
Philipp M, Tessier A, Donnelly M, Fang L, Feng K, Zhao L, Grosser S, Sun G, Sun W, Mentré F, Bertrand J
Model-based bioequivalence approach for sparse pharmacokinetic bioequivalence studies: Model selection or model averaging?.
Statistics in Medicine 2024, 43, 3403-3416.
Reeves S, Bertrand J, Obee SJ, Hunter S, Howard R, Flanagan RJ
A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status.
British Journal of Clinical Pharmacology 2024, 90, 135-145.
Guhl M, Bertrand J, Fayette L, Mercier F, Comets E
Uncertainty Computation at Finite Distance in Nonlinear Mixed Effects Models-a New Method Based on Metropolis-Hastings Algorithm.
The AAPS journal 2024, 26, 53.
2023
Tardivon C, Loingeville F, Donnelly M, Feng K, Sun W, Sun G, Grosser S, Zhao L, Fang L, Mentré F, Bertrand J
Evaluation of model-based bioequivalence approach for single sample pharmacokinetic studies.
CPT: pharmacometrics & systems pharmacology 2023, 12, 904-915.
Goulenok T, Seurat J, Selle AdL, Jullien V, Leflon-Guibout V, Grall N, Lescure FX, Lepeule R, Bertrand J, Fantin B, Burdet C, Lefort A
Pharmacokinetic interaction between rifampicin and clindamycin in staphylococcal osteoarticular infections.
International Journal of Antimicrobial Agents 2023, 62, 106885.
Roughley M, Bertrand J, Reeves S
The Yale University Open Data Access Project: A Resource for Research in Psychopharmacology.
Journal of Clinical Psychopharmacology 2023, 43, 479-481.
Roughley M, Mena C, Howard R, Reeves S, Bertrand J
Guiding safer risperidone prescribing in Alzheimer's disease with therapeutic drug monitoring.
British Journal of Clinical Pharmacology 2023, 89, 2316-2321.
Kerioui M, Beaulieu M, Desmée S, Bertrand J, Mercier F, Jin JY, Bruno R, Guedj J
Nonlinear multilevel joint model for individual lesion kinetics and survival to characterize intra-individual heterogeneity in patients with advanced cancer.
Biometrics 2023
Bertrand J, Barrail-Tran A, Fayette L, Savic R, Goujard C, Teicher E, Barau C, Pruvost A, Taburet AM, Mentré F, Verstuyft C
Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records.
Antimicrobial Agents and Chemotherapy 2023, 67, e0233918.
Kerioui M, Bertrand J, Desmée S, Le Tourneau C, Mercier F, Bruno R, Guedj J
Assessing the Increased Variability in Individual Lesion Kinetics During Immunotherapy: Does It Exist, and Does It Matter?.
JCO precision oncology 2023, 7, e2200368.
Marc A, Marlin R, Donati F, Prague M, Kerioui M, Hérate C, Alexandre M, Dereuddre-Bosquet N, Bertrand J, Contreras V, Behillil S, Maisonnasse P, Van Der Werf S, Le Grand R, Guedj J
Impact of variants of concern on SARS-CoV-2 viral dynamics in non-human primates.
PLoS computational biology 2023, 19, e1010721.
2022
Guhl M, Mercier F, Hofmann C, Sharan S, Donnelly M, Feng K, Sun W, Sun G, Grosser S, Zhao L, Fang L, Mentré F, Comets E, Bertrand J
Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies.
Journal of Pharmacokinetics and Pharmacodynamics 2022, 49, 557-577.
Möllenhoff K, Loingeville F, Bertrand J, Nguyen TT, Sharan S, Zhao L, Fang L, Sun G, Grosser S, Mentré F, Dette H
Efficient model-based bioequivalence testing.
Biostatistics (Oxford, England) 2022, 23, 314-327.
Kerioui M, Bertrand J, Bruno R, Mercier F, Guedj J, Desmée S
Modelling the association between biomarkers and clinical outcome: An introduction to nonlinear joint models.
British Journal of Clinical Pharmacology 2022, 88, 1452-1463.
2021
Couffignal C, Mentré F, Bertrand J
Impact of study design and statistical model in pharmacogenetic studies with gene-treatment interaction.
CPT: pharmacometrics & systems pharmacology 2021, 10, 340-349.
Reeves S, Bertrand J, Uchida H, Yoshida K, Otani Y, Ozer M, Liu KY, Bramon E, Bies R, Pollock BG, Howard R
Towards safer risperidone prescribing in Alzheimer's disease.
The British Journal of Psychiatry: The Journal of Mental Science 2021, 218, 268-275.
Marc A, Kerioui M, Blanquart F, Bertrand J, Mitjà O, Corbacho-Monné M, Marks M, Guedj J
Quantifying the relationship between SARS-CoV-2 viral load and infectiousness.
eLife 2021, 10, e69302.
2020
Gonçalves A, Bertrand J, Ke R, Comets E, de Lamballerie X, Malvy D, Pizzorno A, Terrier O, Rosa Calatrava M, Mentré F, Smith P, Perelson AS, Guedj J
Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load.
CPT: pharmacometrics & systems pharmacology 2020, 9, 509-514.
Kerioui M, Mercier F, Bertrand J, Tardivon C, Bruno R, Guedj J, Desmée S
Bayesian inference using Hamiltonian Monte-Carlo algorithm for nonlinear joint modeling in the context of cancer immunotherapy.
Statistics in Medicine 2020, 39, 4853-4868.
Riglet F, Bertrand J, Barrail-Tran A, Verstuyft C, Michelon H, Benech H, Durrbach A, Furlan V, Barau C
Population Pharmacokinetic Model of Plasma and Cellular Mycophenolic Acid in Kidney Transplant Patients from the CIMTRE Study.
Drugs in R&D 2020, 20, 331-342.
Riglet F, Mentre F, Veyrat-Follet C, Bertrand J
Bayesian Individual Dynamic Predictions with Uncertainty of Longitudinal Biomarkers and Risks of Survival Events in a Joint Modelling Framework: a Comparison Between Stan, Monolix, and NONMEM.
The AAPS journal 2020, 22, 50.
Loingeville F, Bertrand J, Nguyen TT, Sharan S, Feng K, Sun W, Han J, Grosser S, Zhao L, Fang L, Möllenhoff K, Dette H, Mentré F
New Model-Based Bioequivalence Statistical Approaches for Pharmacokinetic Studies with Sparse Sampling.
The AAPS journal 2020, 22, 141.
2019
D'Antonio F, Reeves S, Sheng Y, McLachlan E, de Lena C, Howard R, Bertrand J
Misidentification Subtype of Alzheimer's Disease Psychosis Predicts a Faster Cognitive Decline.
CPT: pharmacometrics & systems pharmacology 2019, 8, 308-315.
Couffignal C, Bertrand J, Sportiche S, Jarroir M, El Balkhi S, Djebrani-Oussedik N, Poupon J, Declèves X, Mentré F, Bellivier F
Population pharmacokinetic modeling of sustained release lithium in the serum, erythrocytes and urine of patients with bipolar disorder.
European Journal of Clinical Pharmacology 2019, 75, 519-528.
2018
Reeves S, Eggleston K, Cort E, McLachlan E, Brownings S, Nair A, Greaves S, Smith A, Dunn J, Marsden P, Kessler R, Taylor D, Bertrand J, Howard R
Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP).
International Journal of Geriatric Psychiatry 2018, 33, 396-404.
Lê MP, Chaix ML, Chevret S, Bertrand J, Raffi F, Gallien S, El Abbassi EMB, Katlama C, Delobel P, Yazdanpanah Y, Saillard J, Molina JM, Peytavin G, ANRS 165 DARULIGHT Study Group
Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
The Journal of Antimicrobial Chemotherapy 2018, 73, 2120-2128.
2017
Reeves S, McLachlan E, Bertrand J, Antonio FD, Brownings S, Nair A, Greaves S, Smith A, Taylor D, Dunn J, Marsden P, Kessler R, Howard R
Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
Brain: A Journal of Neurology 2017, 140, 1117-1127.
Eloy P, Tessier A, Fan-Havard P, Chou M, Verstuyft C, Taburet AM, Haas DW, Bertrand J, ANRS12154 Study Group
Genetics of Nevirapine Metabolic Pathways at Steady State in HIV-Infected Cambodians.
Antimicrobial Agents and Chemotherapy 2017, 61, e00733-17.
Reeves S, Bertrand J, McLachlan E, D'Antonio F, Brownings S, Nair A, Greaves S, Smith A, Dunn JT, Marsden P, Kessler R, Uchida H, Taylor D, Howard R
A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease.
The Journal of Clinical Psychiatry 2017, 78, e844-e851.
2016
Tessier A, Bertrand J, Chenel M, Comets E
Combined Analysis of Phase I and Phase II Data to Enhance the Power of Pharmacogenetic Tests.
CPT: pharmacometrics & systems pharmacology 2016, 5, 123–131.
Reeves S, Bertrand J, D'Antonio F, McLachlan E, Nair A, Brownings S, Greaves S, Smith A, Taylor D, Howard R
A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's disease.
Psychopharmacology 2016, 233, 3371-3381.
Jagani M, Legay H, Ranmal SR, Bertrand J, Ooi K, Tuleu C
Can a Flavored Spray (Pill Glide) Help Children Swallow Their Medicines? A Pilot Study.
Pediatrics 2016, 138,
2015
Bertrand J, De Iorio M, Balding DJ
Integrating dynamic mixed-effect modelling and penalized regression to explore genetic association with pharmacokinetics.
Pharmacogenetics and Genomics 2015, 25, 231–238.
Tessier A, Bertrand J, Chenel M, Comets E
Comparison of Nonlinear Mixed Effects Models and Noncompartmental Approaches in Detecting Pharmacogenetic Covariates.
The AAPS journal 2015, 17, 597–608.
2014
Bertrand J, Verstuyft C, Chou M, Borand L, Chea P, Nay KH, Blanc FX, Mentré F, Taburet AM, CAMELIA (ANRS 1295-CIPRA KH001) Study Group
Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.
The Journal of Infectious Diseases 2014, 209, 399–408.
2013
Bertrand J, Balding DJ
Multiple single nucleotide polymorphism analysis using penalized regression in nonlinear mixed-effect pharmacokinetic models.
Pharmacogenetics and Genomics 2013, 23, 167–174.
2012
Bertrand J, Chou M, Richardson DM, Verstuyft C, Leger PD, Mentré F, Taburet AM, Haas DW, ANRS 12154 Study Group
Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.
Pharmacogenetics and Genomics 2012, 22, 868–876.
Bertrand J, Comets E, Chenel M, Mentré F
Some alternatives to asymptotic tests for the analysis of pharmacogenetic data using nonlinear mixed effects models.
Biometrics 2012, 68, 146–155.
Plan EL, Maloney A, Mentré F, Karlsson MO, Bertrand J
Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models.
The AAPS journal 2012, 14, 420–432.
2011
Bertrand J, Laffont CM, Mentré F, Chenel M, Comets E
Development of a complex parent-metabolite joint population pharmacokinetic model.
The AAPS journal 2011, 13, 390-404.
2010
Chou M, Bertrand J, Segeral O, Verstuyft C, Borand L, Comets E, Le Tiec C, Becquemont L, Ouk V, Mentre F, Taburet AM
Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.
Antimicrobial Agents and Chemotherapy 2010, 54, 4432-4439.
2009
Bertrand J, Treluyer JM, Panhard X, Tran A, Auleley S, Rey E, Salmon-Céron D, Duval X, Mentré F, COPHAR2-ANRS 111 Study Group
Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.
European Journal of Clinical Pharmacology 2009, 65, 667-678.
Bertrand J, Comets E, Laffont CM, Chenel M, Mentré F
Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.
Journal of Pharmacokinetics and Pharmacodynamics 2009, 36, 317-339.
2008
Bertrand J, Comets E, Mentre F
Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters.
Journal of Biopharmaceutical Statistics 2008, 18, 1084-1102.